Tomita Masaki, Shimizu Tetsuya, Hara Masaki, Ayabe Takanori, Onitsuka Toshio
Department of Surgery II, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, Japan.
Anticancer Res. 2008 May-Jun;28(3B):1947-50.
Only a few studies have reported any prognostic impact of the preoperative hemoglobin level itself in resectable non-small cell lung cancer (NSCLC). The survival impact of preoperative hemoglobin level and the relationship between hemoglobin and serum CEA level were investigated.
Two hundred and forty consecutive NSCLC patients were reviewed retrospectively.
The 5-year survival of patients with low and those with a normal hemoglobin level was 42.99% and 73.47%, respectively. Both univariate and multivariate analyses indicated the independent prognostic impact of the hemoglobin level. The result for stage I patients was identical. Patients with normal hemoglobin could be subdivided into 2 groups based on their serum CEA level; the 5-year survival of patients with normal and those with elevated CEA was 81.72% and 57.24%, respectively.
The preoperative hemoglobin level was a prognostic factor for NSCLC patients. The combined use of hemoglobin and CEA levels might be useful to predict the prognosis of patients.
仅有少数研究报道了术前血红蛋白水平本身对可切除的非小细胞肺癌（NSCLC）的预后影响。本研究调查了术前血红蛋白水平对生存的影响以及血红蛋白与血清癌胚抗原（CEA）水平之间的关系。
回顾性分析了240例连续的NSCLC患者。
血红蛋白水平低和正常的患者5年生存率分别为42.99%和73.47%。单因素和多因素分析均表明血红蛋白水平具有独立的预后影响。I期患者的结果相同。血红蛋白水平正常的患者可根据其血清CEA水平分为两组；CEA水平正常和升高的患者5年生存率分别为81.72%和57.24%。
术前血红蛋白水平是NSCLC患者的一个预后因素。联合使用血红蛋白和CEA水平可能有助于预测患者的预后。
